The ToxoReTREAT project will offer new, improved approaches to the diagnosis and treatment of reactivated toxoplasmosis (RT) in the growing population of allogeneic hematopoietic stem cell recipients. Using a multidisciplinary approach, we will formulate national guidelines for the diagnosis and treatment of RT, examine the efficacy of newly synthesized acridine and acridone derivatives in experimental models of RT, using the freely available ImageJ software for computer analysis of experimental results.
Toxoplasma gondii, the causative agent of toxoplasmosis, is a parasitic protozoan that infects almost a third of the global population. In cases of profound prolonged immunosuppression, reactivation of the infection occurs in chronically infected individuals, which can be life-threatening. Reactivated toxoplasmosis (RT) is a particularly devastating complication in allogeneic hematopoietic stem cell recipients, who represent the fastest growing population of immunosuppressed patients in Europe. Despite this, there are still no guidelines for the diagnosis and treatment of RT. Moreover, the limited therapeutic options for RT are not only inadequate for allogeneic hematopoietic stem cell recipients due to pronounced myelotoxicity, but also ineffective since they only act on circulating parasites. The ToxoReTREAT project is aimed at solving the problem of RT in this patient population by providing new therapeutic options, with improved efficiency and reduced side effects, and formulating national guidelines for the diagnosis and treatment of RT.
The main goal of the ToxoReTREAT project is to solve the problem of reactivated toxoplasmosis (RT) in the population of recipients of allogeneic hematopoietic stem cells by applying a multidisciplinary approach (medicine, pharmaceutical chemistry, software analysis) to finding new therapeutic options, improved efficiency and reduced side effects, and formulating national guidelines for diagnostics and treatment of RT.
Институт за медицинска истраживања
